Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of YL201 + serplulimab versus carboplatin + etoposide + serplulimab in extensive-stage small cell lung cancer
CTR20262873Phase 3Active
- Sponsor
- MediLink Therapeutics
- Start
- Aug 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of YL201, serplulimab, carboplatin, etoposide in small cell lung cancer (SCLC), sponsored by MediLink Therapeutics. Started Aug 2026; status: active.
02
Drugs
YL201serplulimabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20262873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262873.